Fig. 2: Target engagement.
From: Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors
a Mean (SD) ADMA-R225-hnRNP-A1 in PBMCs in blood. b Mean (SD) plasma circulating free ADMA. c Tumor ADMA-R225-hnRNP-A1 (IHC)a. d Tumor ADMA-R225-hnRNP-A1 (LC-MS)b. ADMA asymmetric dimethylarginine, DE dose-escalation cohort, ICH immunohistochemistry, LC-MS liquid chromatography-mass spectrometry, PBMC peripheral blood mononuclear cells, PD pharmacodynamic, PK pharmacokinetic. aIHC: formalin-fixed paraffin-embedded tumor biopsy. bLC-MS: fresh frozen tumor biopsy.
